Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is lower after the company reported mixed Q4 and full-year 2013 earnings, as well as releasing results for its Phase 3 POISE trial. Shares are now down 10.71% at $412.75, but are still at the higher end of its 52-week range of $30.38 – $497.00 On Friday, Intercept (NASDAQ:ICPT) reported a loss per share of $0.64, compared to a loss of … Continue reading Healthcare Movers: Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Pernix Therapeutics (NASDAQ:PTX), Galena Biopharma (NASDAQ:GALE), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)